Biological and pharmacokinetic studies indicate that the anti-tubercular drug, delamanid, could be repurposed for the treatment of visceral leishmaniasis.

Genomic data for the parasites that cause visceral leishmaniasis provides the first global picture of the diversity and evolution of the pathogen and the epidemiology of this fatal tropical disease.

Maps defining environmental risk of the leishmaniases provide insights into the ecology of these diseases and identify regions to target public health measures and inform future burden estimates.

Genome sequencing reveals the evolution and epidemiology of Leishmania donovani in the Indian subcontinent, where epidemics have caused up to 30,000 deaths per year.

LeishBASEedit enables gene editing in Leishmania without requiring DNA double-strand breaks, homologous recombination, or donor DNA, thereby facilitating loss-of-function screens via delivery of plasmid libraries and regardless of limitations due to gene copy number variations and/or lack of RNAi components.

Upon Toxoplasma gondii infection, IL-33 plays a critical role in driving early anti-parasite responses by innate lymphoid cells rendered responsive to its effects by infection.

Following exposure of Leishmania culture promastigotes to DNA stress, single-cell RNA sequencing reveals discrete clusters of cells associated with efficient generation of hybrids between different species and strains in vitro marked by expression of the ancestral gamete fusogen HAP2.

A new screening strategy for divergent homologs of insect odorant and gustatory receptors, based upon predicted three-dimensional structural similarity, unexpectedly identifies candidates in humans.

Eugenol has the ability to improve the type 1 diabetes mellitus through NRF2-mediated oxidative stress pathway.

Isoform-specific transcript localization underlies the evolutionary diversity of anterior axis determinants in embryos of dipteran insects.